Bristol-Myers lung cancer drug in trouble, stock price falls 10 percent. This is an immunotherapy drug. Many other companies have had trouble with this approach, usually safety concerns.

Quote:

---

The company did not say whether the data was disappointing or merely insufficient to seek accelerated approval.

---

http://finance.yahoo.com/news/bristol-myers-s...05197.html